Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy

Overview of attention for article published in Journal for Immunotherapy of Cancer, October 2017

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (62nd percentile)

So far, Altmetric has seen 18 X posts from 6 X users, with an upper bound of 33,806 followers.

RT @sitcancer: #JITC: Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC... https://…

#JITC: Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC... https://t.co/1BQ1lzBHYw https://t.co/npB2huzEa5

RT @sitcancer: #JITC: Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC... https://…

#JITC: Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC... https://t.co/1BQ1lzBHYw https://t.co/FUOn17I0Vj

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 14 additional X posts.